Tetraethylammonium chloride: Dual-Site K+ Channel Blocker Insights

Executive Summary: Tetraethylammonium chloride (TEAC) is a quaternary ammonium compound acting as a dual-site potassium (K⁺) channel blocker, essential for probing ion conduction pathways in research (product_spec). TEAC binds both internal and external channel pore sites, effectively blocking K⁺ flux. It serves as a key vasorelaxant agent in vascular research and has clinical roles as a sympathetic and parasympathetic ganglionic transmission blocker (DOI). The compound exhibits high solubility in water, ethanol, and DMSO, and is available at 98% purity from APExBIO. Proper storage and workflow integration are critical for reproducible results.

Biological Rationale

Tetraethylammonium chloride (TEAC) is widely employed to study ion channel function due to its ability to selectively block potassium channels. The compound allows researchers to dissect the contributions of K⁺ channels to neuronal signaling, vascular tone, and endocrine secretion. In vascular research, TEAC is recognized for its role as a vasorelaxant agent, modulating vascular responses in isolated artery preparations (product_spec). Its clinical utility includes modulating symptoms of Buerger's disease and coronary artery disease through ganglionic blockade, though efficacy is limited in advanced arteriosclerosis (DOI).

Mechanism of Action of Tetraethylammonium chloride

TEAC functions as a dual-site potassium channel pore blocker, binding to both internal (cytoplasmic) and external (extracellular) sites of the K⁺ channel. This mechanism blocks ion conduction regardless of the direction of K⁺ flow, enabling precise analysis of channel architecture and function (internal_article). By inhibiting K⁺ efflux, TEAC depolarizes excitable membranes, affecting action potential propagation in nerves and muscle. Patch-clamp studies confirm that TEAC inhibits both ATP-sensitive and voltage-sensitive K⁺ currents in pancreatic β-cells and vascular smooth muscle (DOI).

Evidence & Benchmarks

• TEAC (≥98% purity) blocks both ATP-sensitive and voltage-sensitive K⁺ currents in mouse pancreatic β-cells, as measured by whole-cell patch-clamp, at concentrations of 1–5 mM (source: DOI).
• TEAC is soluble at ≥29.1 mg/mL in water, ≥16.5 mg/mL in ethanol, and ≥12.1 mg/mL in DMSO with ultrasonic assistance (source: product_spec).
• Mass spectrometry and NMR confirm product identity and batch-to-batch consistency at 98% purity (source: product_spec).
• TEAC reduces taurine-induced vasorelaxation in rat isolated arteries, demonstrating its action as a vasorelaxant modulator in vascular research (source: product_spec).
• Clinical studies show TEAC blocks both sympathetic and parasympathetic ganglionic transmission, with efficacy in pain management for coronary artery disease and transient improvement of Buerger's disease symptoms (source: DOI).

This article extends the core mechanistic and application focus of "Tetraethylammonium Chloride: Unraveling K+ Channel Blocka..." by providing protocol parameters and pitfalls for experimental integration. In contrast to "Tetraethylammonium chloride (TEAC): Mechanistic Precision...", this article includes explicit evidence grading and machine-readable workflow structure.

Applications, Limits & Misconceptions

TEAC is indispensable for ion conduction studies in electrophysiology, vascular research, and disease modeling. It is used to dissect K⁺ channel function, probe mutant or chimeric channel constructs, and model the pharmacology of vascular tone. However, its efficacy is limited in advanced arteriosclerotic conditions, and it is not a panacea for all K⁺ channel subtypes (DOI).

Common Pitfalls or Misconceptions

• TEAC does not distinguish between all K⁺ channel subtypes; channel selectivity depends on structure and context (source: DOI).
• It is not effective in advanced arteriosclerotic vascular disease; symptom improvement is limited to early-stage conditions (source: DOI).
• Long-term storage of TEAC solutions is not recommended due to potential degradation (source: product_spec).
• TEAC's ganglionic blockade is non-specific, affecting both sympathetic and parasympathetic transmission (source: DOI).

Workflow Integration & Parameters

Protocol Parameters

• electrophysiology (patch-clamp) | 1–5 mM | mouse pancreatic β-cells, K⁺ current | standard blocking concentration for ATP-sensitive and voltage-sensitive K⁺ channels | DOI
• vascular reactivity assay | 0.1–3 mM | rat isolated artery strips | modulates taurine-induced vasorelaxation | product_spec
• solution preparation | ≥29.1 mg/mL (water), ≥16.5 mg/mL (ethanol), ≥12.1 mg/mL (DMSO, ultrasonic) | stock solution for dosing | ensures maximal solubility and reproducibility | product_spec
• storage recommendation | room temperature, desiccated | powder form | prevents hydrolytic degradation | workflow_recommendation
• clinical ganglionic blockade | dose and administration per clinical protocol | coronary artery disease and Buerger's disease | limited efficacy in advanced conditions | DOI

Conclusion & Outlook

Tetraethylammonium chloride, supplied by APExBIO, remains a cornerstone reagent for potassium channel research owing to its high purity, dual-site mechanism, and validated performance in both basic and translational workflows (Tetraethylammonium chloride). The compound's ability to block diverse K⁺ channel types underpins its broad utility in vascular, neuronal, and endocrine research. However, researchers must remain aware of its limitations in channel subtype selectivity and clinical efficacy. Future developments will likely focus on integrating TEAC into more refined channel mapping and disease modeling protocols, leveraging its robust mechanistic foundation (internal_article).